Investing, Biotechnology, Venture Capital, Science, Immune System.
immunotherapy. However, despite the early FDA approvals of interleukin-2 (IL-2) and interferon-α (IFNα) for cancer treatment over 30 years ago, cytokine therapies have largely failed to achieve significant success in the clinic due to narrow therapeutic windows and dose-limiting toxicities. The